Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 1018-1031
DOI: 10.3350/cmh.2024.1183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Hye Won Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yonsei University College of Medicine, Korean Association for the Study of the Liver.
Abstract (Originalsprache)
Background/Aims: Recently, the Korean Association for the Study of the Liver (KASL) introduced a noninvasive test-based approach that uses the fibrosis-4 (FIB-4) index followed by vibration-controlled transient elastography (VCTE) to identify high-risk patients with metabolic-associated steatotic liver disease (MASLD). In this study, the KASL two-step approach was validated by assessing the risk of liver-related event (LRE) development.
Methods
We retrospectively analyzed 8,131 patients with MASLD who underwent VCTE between 2012 and 2020. The index date was defined as the date of the VCTE measurement. Using the KASL two-step approach (FIB-4 index and subsequent VCTE), patients were stratified into four groups (low-, intermediate-low-, intermediate-high-, and high-risk groups). Outcomes, including LREs such as decompensation (DCC) or hepatocellular carcinoma (HCC) were evaluated.
Results
During the follow-up (median 46.6 months), 86 (1.1%) patients developed LREs (39 [0.5%] with DCC and 47 [0.6%] with HCC). The KASL two-step approach classified 67.6%, 17.7%, 5.7% and 9.0% of patients in the low-, intermediate-low-, intermediate-high-, and high-risk groups, respectively. The cumulative incidences of LREs increased proportionally according to risk stratification (0.07%, 0.10%, 0.29%, and 1.51% at 3 years and 0.35%, 0.26%, 1.94% and 5.46% at 5 years). The overall accuracy in predicting LREs ranged from 67.7–99.8%. The FIB-4 index and subsequent Agile3+, Agile 4, or FibroScan aspartate aminotransferase scores showed similar predictive abilities compared to the KASL approach.
Conclusions
The KASL two-step approach is an effective and practical method for risk stratification in patients with MASLD, optimizing patient care through early identification of high-risk individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Korea.
Förderung
- Yonsei University College of Medicine
- Korean Association for the Study of the Liver
Zitieren
APA
Lee, H. W., Lee, J. S., Kim, M. N., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2025). Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 31(3), 1018-1031. https://doi.org/10.3350/cmh.2024.1183
Vancouver
Lee HW, Lee JS, Kim MN, Kim BK, Park JY, Kim DY, et al. Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2025;31(3):1018-1031. doi:10.3350/cmh.2024.1183
BibTeX
@article{Lee2025,
author = {Lee, Hye Won and Lee, Jae Seung and Kim, Mi Na and Kim, Beom Kyung and Park, Jun Yong and Kim, Do Young and Ahn, Sang Hoon and Kim, Seung Up},
title = {Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {3},
pages = {1018--1031},
doi = {10.3350/cmh.2024.1183}
}
EUVIMED